Celebrex in treatment of joint diseases in patients with risk factors of gastropathy and cardiovascular palhalodydevelopment
https://doi.org/10.14412/1995-4484-2004-1381
Abstract
References
1. <div><p>Adams P.F., G.E Hendershot М.А. Marano. Current Estimates from the National Health Interview Survey 1996. National Center for Health Statistics. Vital Health Stat. 10 (2000) , 1999.</p><p>Vane J.R, Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol.), 1971, 231, 232-235</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине) М., "Анко", 2000, 143 стр</p><p>Singh G., Diadohlopoulus G. Epidemiology of NSAID’S- induced gastroduodenal complication J. Rheumatol., 1999. 26 suppl., 18-24</p><p>Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complication of peptic ulceration. Gut, 1987, 28, 527-532</p><p>Singh G., Ramey D.R., Morfield D. et.al. Gastrointestinal tract complications on nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Arch. Intern. Med. 1996, 156, 1530-1536</p><p>Goldstein J., Boers М., Van Ingen H. et. al. Endoscopic gastroduodenal ulcers and age: increased incidence with traditional NSAIDs but non with Celecoxib. Abstr. accepted to: United Europen Gastroenterology Week (UEGW); Geneva, Oct. 19-24, 2002.</p><p>Janssen М., Dijkmans B., van der Sluijs F.A. Upper gastrointestinal complaints and complication in chronic rheumatic patients in comparison with other chronic diseases. Br.J.Rheum., 1992., 31, 747-752.</p><p>Насонов Е.Л. Ингибиторы циклооксигеназы 2: современная концепция. Тер. архив, 1999, II, 54-57.</p><p>Bensen W.G., Zhao S.Z., Burke Т.А. et.al. Upper gastrointestinal tolerability of Celecoxib, a COX-2 specific inhibitor, compared to napoxen and placebo. J. Rheum., 2000, 27, 1876-1883</p><p>Feldman М., McMahon A.T. Do cyclooxigenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med., 2000, 132,134-139</p><p>E.C. Цветкова, Л.И. Алексеева. P.M. Балабанова и др. Эффективность и переносимость целебрекса при осте- артрозе (данные Российского исследования), Тер.ар- хив., 2001,5, 61-63</p><p>А.Е. Каратеев. Гастродуоденальная переносимость це- лекокснба (целебрекса) у больных остеоартрозом: эндоскопическая оценка. Тер. архив, 2001, 5, 63-64.</p><p>Epstein М., Safar М. Cardiovascular and renal effects of COX-2 specific inhibitors: emerging pathophysiological and clinical perspectives. J. Hypert., 2002, 20 (suppl. 6), 1-2</p><p>Whelton A., Fort J.G., Puma J.A. et.al. Cyclooxigenase-2 specific inhibitors and cardiorenal function: a randomized, controlled trial. Am. J. Ther., 2001, 9, 85-95</p><p>Solomon D.H., Glynn R., Levin R., Adams K, Nonsteroidal anti-inflammatory drugs and acute Myocardial Infarction. Arch. Int. Med., 2002, 162, 10671074.</p></div><br />
Review
For citations:
Chichasova N.V., Imametdinova G.R., Nassonov E.L. Celebrex in treatment of joint diseases in patients with risk factors of gastropathy and cardiovascular palhalodydevelopment. Rheumatology Science and Practice. 2004;42(1):39-42. (In Russ.) https://doi.org/10.14412/1995-4484-2004-1381